U.S. pharma giant copyright scrapped two experimental weight loss products very last 12 months—a after-each day tablet, lotiglipron, on account of elevated liver enzymes as well as a twice-daily tablet, danuglipron, due to sturdy side effects—but CEO Albert Bourla has explained the company is set to “Engage in and earn” within the weight pr